Get the Stockscreener App
29.50
0.10%
-0.03
After Hours:
29.52
0.02
+0.07%
Metsera Inc stock is traded at $29.50, with a volume of 383.68K.
It is down -0.10% in the last 24 hours and up +0.00% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$29.53
Open:
$28.89
24h Volume:
383.68K
Relative Volume:
5.04
Market Cap:
$3.04B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$28.77
$30.26
1-Week Range:
$25.06
$30.26
52-Week Range:
$25.06
$30.26
Metsera Inc Stock (MTSR) Company Profile
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
29.50 | 3.04B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metsera Inc Stock (MTSR) Latest News
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Metsera sees stock rally 54% following $275M IPO - MSN
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut -January 31, 2025 at 01:02 pm EST - Marketscreener.com
Metsera Shares Rise Sharply in Nasdaq Debut -January 31, 2025 at 01:03 pm EST - Marketscreener.com
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon - MarketWatch
MTSR IPO NewsObesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - Renaissance Capital
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera Prices of Initial Public Offering - citybiz
Metsera, Maze raise a combined $415M in IPO double-header - FirstWord Pharma
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
MTSRMetsera, Inc. Latest Stock News & Market Updates - StockTitan
Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut - Smartkarma
Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha
GLP-1RA developer Metsera targets $289m IPO - Pharmaceutical Technology
Three biotechs go public as IPO momentum increases - The Pharma Letter
Obesity drug developer Metsera sets terms for $275M IPO - MSN
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation - Smartkarma
Metsera Seeks $289M Raise, $1.78B Valuation in IPO - BioSpace
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Metsera eyes $289M IPO to fund phase 3 weight loss trial - Fierce Biotech
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - Yahoo Finance
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO - MSN
Metsera outlines $250M IPO plans as obesity biotech competition rises - Endpoints News
Weight-loss drug developer Metsera reveals wider loss in US IPO filing - MSN
Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech - Smartkarma
2024’s Top 7 VC Raises in Biotech - BioSpace
Obesity drug developer Metsera files for $100M IPO - MSN
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metsera Inc Stock (MTSR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):